Background and Aim: Little is known about the risk of serious infection when combining antitumour necrosis factor [TNF] therapy for refractory inflammatory bowel disease [IBD] with immunosuppression after liver transplantation [LT]. Our aim was to investigate the infection risk in this patient group by systematic review and meta-analysis of the available data. Methods: A search was conducted for full papers and conference proceedings through September 2015, regarding liver transplant recipients and anti-TNF therapy. All studies were appraised using the adapted Newcastle-Ottawa Scale [NOS]. Two reviewers independently extracted patient data Results: In all 465 articles and abstracts were identified, of which eight were included. These contained 53 post-LT patients on anti-TNF therapy and 23 post-LT patients not exposed to anti-TNF therapy. From the LUMC LT-cohort, 41 PSC patients with PSC-IBD not exposed to anti-TNF therapy were included as control population. The infection rate for TNF-exposed patients was 0.168 serious infections per patient year, compared with 0.149 in the control patients (rate ratio 1.12 [95% confidence interval: 0.233-5.404, P = 0.886]. When correcting for time since transplant, the infection rate was 0.194 in the TNF-exposed vs 0.115 in the non-exposed [p = 0.219]. Conclusions: No significant increase in the rate of serious infection was observed in LT recipients with PSC-IBD during exposure to anti-TNF therapy.
Introduction
Primary sclerosing cholangitis [PSC] is an inflammatory and fibrosing liver disease involving the intra-and extrahepatic biliary tract. As no pharmaceutical or other disease-modifying therapeutic agent is available, a substantial portion of the patients eventually progress to end-stage liver disease or develop cholangiocarcinoma, requiring liver transplantation [LT] . 1 Nearly 70% of PSC patients have concurrent inflammatory bowel disease [IBD] 3 and, after liver transplantation, IBD activity increases in one-third of patients. 4 This group poses a difficulty for the treating physician when mucosal healing is not achieved with conventional anti-inflammatory drugs. Anti-TNF therapy has been shown to be effective in both inducing and maintaining remission in IBD patients with refractory disease, 5 but was associated with an increase in the incidence of [serious] infections in some studies. 6 In liver transplant recipients, infections are important cause of mortality after LT. 7, 8 Data on the risk of serious infection when combining anti-TNF therapy for IBD treatment with immunosuppression for prevention of rejection are scarce. To assess the safety of anti-TNF therapy in these patients, we performed a systematic review and meta-analysis in order to calculate and compare the serious infection rate in liver transplant recipients with and without anti-TNF exposure.
Methods
This study was conducted in accordance with the PRISMA statement. 
Study selection
Two authors independently reviewed the titles and abstracts of the identified papers, letters, and abstracts, and selected them for detailed assessment. These full articles, letters and abstracts were reviewed to select studies eligible for our final analysis. Studies were considered eligible if they met the following criteria: [I] the studies had to report on the incidence of serious infections in post-transplantation patients under treatment with any anti-TNF therapy for IBD; [ group were: liver transplant in history; alive 6 months post-transplant; IBD diagnosis; and no current or previous anti-TNF-therapy.
Data extraction
Two authors independently extracted the following patient and control data from each paper: author, year, study type, number of patients, patient age, number and type of infections, follow-up time, and time since transplant, using standard extraction forms. Serious infections were defined according to the serious adverse event definition of the International Conference on Harmonisation [ICH] guidelines for clinical safety data management.
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If data was missing from a paper, the authors were contacted to obtain this missing data. The same patient data was extracted from patient records for the LUMC control group, after consent from the Leiden University medical Center [LUMC] ethics committee [MEC number G16-004]. Follow-up of LUMC patients started 6 months after [re-]transplant, to correct for the transplantation surgery-related increased infection rate, and ended at death or study end.
Quality assessment
Two authors independently assessed the risk of bias in all eligible studies. All studies were appraised using the adapted NewcastleOttawa Scale [NOS], which contains nine criteria for cohort studies and is adapted to six criteria for case series and case reports. 11 To assess the risk of outcome-reporting bias, all studies were scanned for statements about inclusion of all patients within our inclusion criteria as opposed to statements of patient selection.
Data synthesis and analysis
The patient data waereanalysed using Poisson regression models, with a scale parameter to allow for heterogeneity between studies and with the natural logarithm of the total number of years of follow-up as offset variable, to allow for the between-studies differences in total time at risk. This modelling applies inverse variance weighting and calculates a combined serious infection rate per patient-year [PY] for the anti-TNF group and the control group, resulting in a rate ratio of the two serious infection rates.
Before the analysis, possible confounders were considered. Time between transplant and the start of follow-up, and patient age, were considered factors that could potentially affect serious infection rate and therefore cause confounding in our analysis. To solve this, additional analyses were performed with these factors as covariables. Data were analysed using SPSS v23. Figure 1 describes the search strategy. Initially 465 articles and conference proceedings were found, of which 28 citations were deemed potentially relevant. Finally, eight papers were included in the analysis. Both reviewers agreed on the final selection of these studies. Table 1 shows the total NOS score for each study. None of the studies scored less than 75% of the NOS quality criteria. None of studies received a point on 'demonstration that outcome of interest was not present at start of study', as none reported whether patients had infection at the start of follow-up. It however seems unlikely that anti-TNF therapy was started during a serious infection.
Results
From these studies, data were extracted on 53 patients on anti-TNF therapy and 23 control patients not on anti-TNF therapy. Table 1 shows the patient safety data collected for all patients on anti-TNF therapy. No mortalities were reported in any of the study patients.
We identified 41 patients in the LUMC liver transplant cohort who had IBD and underwent LT. Table 2 shows the characteristics for these included patients. Table 3 shows all control patient data.
Meta-analysis results
As shown in Table 4 , the overall infection rate for TNF-exposed patients was 0.168 serious infections per patient-year, which was similar to the 0.149 per year in the control patients [p = 0. 886].
Age at time of transplant was not associated with the rate ratio for serious infections, whereas the time since transplantation was. Although correcting for time since transplant increase, the difference in infection rates between the anti-TNF-group and the control group 
Sensitivity analysis
We excluded the two case reports, but this did not alter the results. After exclusion of the case reports, time since transplant still influenced [p < 0.001] the infection rates in these groups. The serious infection rate did not differ between groups [p = 0.146].
Discussion
This meta-analysis investigated the safety of anti-TNF therapy in liver transplant recipients with IBD. As no randomised controlled trials [RCTs] were available, a cohort study, case series, and case Table 3 . Control patient data from LUMC cohort and studies. reports were included. Only one cohort study was identified, so data from the Leiden University Medical Centre liver transplant cohort were used as additional control population.
No difference in the serious infection rate between liver transplant recipients with and without anti-TNF therapy was found. However, as the confidence intervals are wide, this does not fully rule out any clinically significant increase in risk due to addition of anti-TNF therapy. However, in the over 100 patient-years of followup during TNF-exposure analysed in this study, no important safety signal was detected. A recent meta-analysis on the safety of anti-TNF therapy in non-transplant IBD patients found no increase in occurrence of serious infections, 12 although other studies found an increase in serious infections after anti-TNF exposure. 6 The serious infection rate found in our study is substantially higher than the number found in the treat registry of serious infections while using infliximab [15/100 patient-years vs 2.4/100 patient-years]. This is not surprising: in LT recipients, infections are a substantial threat to patient survival. For instance, Daniel et al. recently described that 18% of LT recipient mortality is due to infections. 13 Use of anti-TNF therapy does not seem to further increase this risk.
In a study not included in this meta-analysis due to missing data, five patients after LT are treated with infliximab, two of whom develop infectious complications and two develop a post transplant lymphoproliferative disease [PTLD].
14 No clinical benefit was observed in any patient treated with anti-TNF.
The primary limitations of the current analysis are its size and the study types used in the analysis. No RCT and only one cohort study was included. Larger cohort studies would allow for correcting for differences between hospitals or regions in treatment or admission. The only cohort study 15 found no increased risk for infections in the anti-TNF exposed group. In summary, our results suggest that anti-TNF-treatment in combination with LT-associated immunosuppression does not increase the serious infection rate. To further confirm the safety of anti-TNF therapy in post-transplant patients, additional patient data are needed. Table 4 . Meta-analysis: serious infection rates and rate ratio for liver transplant recipients exposed and non-exposed to anti-TNF therapy. 
